肝癌在全球癌症致死率中位列第三, 但其治疗效果仍未达到理想水平. 肝癌研究中的挑战之一是
肝癌高度时空异质性, 侵袭转移能力和抗药性. 因此, 深刻理解和模拟肝癌的免疫微环境对于研究 …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and
accounts for over 80% of primary liver cancer worldwide. Early stage HCC can be treated by …

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in adults and has
one of the highest mortality rates of solid cancers. Ninety percent of HCCs are associated …

Hepatocellular carcinoma (HCC) is a complex heterogeneous disease with high morbidity
and mortality. Recent progress in molecular targeted drugs including multikinase inhibitors …

Liver cancer is one of the dominant causes of cancer-related mortality, and the survival rate
of liver cancer is among the lowest for all cancers. Immunotherapy for hepatocellular …

Despite diagnostic and therapeutic advances, liver cancer kills more than 18 million people
every year worldwide, urging new strategies to model the disease and to improve the current …

Objective As the current therapeutic strategies for human hepatocellular carcinoma (HCC)
have been proven to have limited effectiveness, immunotherapy becomes a compelling way …

Mouse models are the basis of preclinical and translational research in hepatocellular
carcinoma (HCC). Multiple methods exist to induce tumour formation in mice, including …

Background and Aims Recent development of multiple treatments for human hepatocellular
carcinoma (HCC) has allowed for the selection of combination therapy to enhance the …

In the last decade, relevant advances have occurred in the treatment of hepatocellular
carcinoma (HCC), with novel drugs entering the clinical practice, among which tyrosine …